This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management of non-tense ascites

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Initial management consists of bed-rest, reduced salt intake, and spironolactone (50-100 mg per day). A fall in weight of approximately 0.5 kg per day should be aimed for.

If the above measures do not produce a weight reduction then spironolactone is gradually increased to 300 mg per day and then, if necessary, frusemide is added, but only once the spironolactone has reached its maximum dose.

There is a danger that the addition of loop diuretics may precipitate the hepatorenal syndrome; sodium supplements are contraindicated because the total body sodium is excessive in cirrhosis so the hyponatraemia is treated by water restriction or mannitol infusion (which increases free water excretion). If this approach is successful then the patient will require a maintenance dose of spironolactone (50-200 mg/day) and a restricted salt diet.

If a patient has malignant ascites then large doses of frusemide may be required to control ascites.

A Le Veen shunt (peritoneo-venous) may be useful in refractory cases.

If ascitic fluid contains more than 250 WBC per cubic millimetre then empirical treatment with a non-nephrotoxic broad spectrum antibiotic should be commenced.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.